Page last updated: 2024-08-23

daunorubicin and defactinib

daunorubicin has been researched along with defactinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Allert, C; Bauer, M; Besenbeck, B; Blank, MF; Bruckmann, M; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Müller-Tidow, C; Pauli, C; Renders, S; Rohde, C; Trumpp, A; Waclawiczek, A; Wickenhauser, C; Zimmermann, SMN; Zinz, R	1

Other Studies

1 other study(ies) available for daunorubicin and defactinib

Article	Year
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. Leukemia, 2022, Volume: 36, Issue:10 Topics: Animals; Benzamides; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 2; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrazines; Sulfonamides	2022

Article

Year

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Leukemia, 2022, Volume: 36, Issue:10

Topics: Animals; Benzamides; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 2; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrazines; Sulfonamides

2022